Leerink Partnrs Issues Positive Forecast for RXRX Earnings

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX - Free Report) - Stock analysts at Leerink Partnrs raised their Q2 2025 earnings per share estimates for shares of Recursion Pharmaceuticals in a research note issued to investors on Tuesday, June 10th. Leerink Partnrs analyst M. Foroohar now forecasts that the company will post earnings of ($0.27) per share for the quarter, up from their prior forecast of ($0.34). The consensus estimate for Recursion Pharmaceuticals' current full-year earnings is ($1.57) per share. Leerink Partnrs also issued estimates for Recursion Pharmaceuticals' Q3 2025 earnings at ($0.31) EPS, Q4 2025 earnings at ($0.20) EPS, FY2025 earnings at ($1.29) EPS, FY2026 earnings at ($0.81) EPS and FY2027 earnings at ($0.30) EPS.

RXRX has been the topic of a number of other research reports. Cowen reaffirmed a "hold" rating on shares of Recursion Pharmaceuticals in a research note on Friday, February 28th. Needham & Company LLC cut their price objective on Recursion Pharmaceuticals from $11.00 to $8.00 and set a "buy" rating on the stock in a research report on Tuesday, May 6th. Morgan Stanley reduced their target price on Recursion Pharmaceuticals from $10.00 to $8.00 and set an "equal weight" rating on the stock in a report on Thursday, April 10th. Finally, Leerink Partners lowered their target price on Recursion Pharmaceuticals from $7.00 to $6.00 and set a "market perform" rating for the company in a research note on Friday, February 28th. Four analysts have rated the stock with a hold rating and two have assigned a buy rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of "Hold" and an average price target of $7.60.

Recursion Pharmaceuticals Trading Down 4.8%

Recursion Pharmaceuticals stock traded down $0.25 during mid-day trading on Friday, reaching $4.92. 37,439,152 shares of the company traded hands, compared to its average volume of 14,988,808. The company has a debt-to-equity ratio of 0.04, a current ratio of 4.35 and a quick ratio of 4.35. Recursion Pharmaceuticals has a 52-week low of $3.79 and a 52-week high of $12.36. The firm has a market capitalization of $2.00 billion, a price-to-earnings ratio of -3.22 and a beta of 0.84. The firm's 50 day moving average price is $4.87 and its 200 day moving average price is $6.33.

Recursion Pharmaceuticals (NASDAQ:RXRX - Get Free Report) last announced its earnings results on Monday, May 5th. The company reported ($0.50) EPS for the quarter, missing analysts' consensus estimates of ($0.44) by ($0.06). Recursion Pharmaceuticals had a negative net margin of 579.52% and a negative return on equity of 76.56%. The business had revenue of $14.75 million for the quarter, compared to the consensus estimate of $18.12 million. During the same quarter in the prior year, the company earned ($0.39) EPS. Recursion Pharmaceuticals's revenue was up 7.2% compared to the same quarter last year.

Institutional Investors Weigh In On Recursion Pharmaceuticals

Several hedge funds have recently bought and sold shares of RXRX. Brighton Jones LLC lifted its holdings in shares of Recursion Pharmaceuticals by 49.4% during the fourth quarter. Brighton Jones LLC now owns 20,261 shares of the company's stock valued at $137,000 after purchasing an additional 6,699 shares during the last quarter. Stratos Wealth Partners LTD. bought a new position in Recursion Pharmaceuticals during the 4th quarter valued at approximately $112,000. Values First Advisors Inc. raised its stake in Recursion Pharmaceuticals by 49.1% during the fourth quarter. Values First Advisors Inc. now owns 89,775 shares of the company's stock valued at $607,000 after buying an additional 29,552 shares during the last quarter. Rhumbline Advisers boosted its holdings in Recursion Pharmaceuticals by 7.6% in the fourth quarter. Rhumbline Advisers now owns 334,032 shares of the company's stock worth $2,258,000 after acquiring an additional 23,564 shares in the last quarter. Finally, Atria Wealth Solutions Inc. purchased a new stake in shares of Recursion Pharmaceuticals in the fourth quarter worth $75,000. Institutional investors own 89.06% of the company's stock.

Recursion Pharmaceuticals Company Profile

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.